A Phase 1b, Open-label, Dose-escalation Clinical Study Evaluating the Safety of Camsirubicin With Prophylactic Pegfilgrastim in the Treatment of Advanced Soft Tissue Sarcomas

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Camsirubicin (Primary) ; Pegfilgrastim (Primary)
Indications Leiomyosarcoma; Lipoma; Liposarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Adverse reactions

13 May 2024 Status changed from recruiting to discontinued.
28 Mar 2024 According to a Monopar Therapeutics media release, company is presently enrolling patients at the fifth dose level, which is over twice the highest dose reached in any prior camsirubicin clinical trial (650 mg/m2 versus 265 mg/m2).
22 Feb 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com